{
  "$schema": "https://json-schema.org/draft/2020-12/schema",
  "description": "XBRL concept mappings for standardizing financial statement line items. Each key is a standardized label, and the value is an array of XBRL concept names that map to it. Focused on biotech/pharma companies.",
  "version": "0.2.0",
  "requiredFields": [
    "Total Assets",
    "Total Liabilities",
    "Stockholders Equity",
    "Revenue",
    "Net Income (Loss)",
    "Cash Flow from Operations",
    "Shares Outstanding (Diluted)"
  ],
  "mappings": {
    "Cash and Cash Equivalents": {
      "concepts": [
        "us-gaap:CashAndCashEquivalentsAtCarryingValue",
        "us-gaap:Cash",
        "us-gaap:CashAndCashEquivalents",
        "us-gaap:CashCashEquivalentsAndShortTermInvestments"
      ],
      "notes": "Primary liquidity measure. Some companies include short-term investments."
    },
    "Research and Development Expense": {
      "concepts": [
        "us-gaap:ResearchAndDevelopmentExpense",
        "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
        "us-gaap:ResearchAndDevelopmentCosts"
      ],
      "notes": "Core metric for biotech burn rate. Excludes IPR&D write-offs in second variant."
    },
    "General and Administrative Expense": {
      "concepts": [
        "us-gaap:GeneralAndAdministrativeExpense",
        "us-gaap:SellingGeneralAndAdministrativeExpense"
      ],
      "notes": "G&A or SG&A depending on company stage (pre-commercial vs commercial)."
    },
    "Selling and Marketing Expense": {
      "concepts": [
        "us-gaap:SellingAndMarketingExpense",
        "us-gaap:SellingExpense"
      ],
      "notes": "Commercial stage companies break out sales/marketing separately."
    },
    "Total Operating Expenses": {
      "concepts": [
        "us-gaap:OperatingExpenses",
        "us-gaap:CostsAndExpenses"
      ],
      "notes": "Sum of R&D + G&A + COGS for burn calculation."
    },
    "Long-Term Debt": {
      "concepts": [
        "us-gaap:LongTermDebt",
        "us-gaap:LongTermDebtNoncurrent",
        "us-gaap:LongTermDebtAndCapitalLeaseObligations"
      ],
      "notes": "Non-current portion of debt. May include capital leases."
    },
    "Short-Term Debt": {
      "concepts": [
        "us-gaap:DebtCurrent",
        "us-gaap:ShortTermBorrowings",
        "us-gaap:LongTermDebtCurrent",
        "us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent"
      ],
      "notes": "Current portion of long-term debt + short-term borrowings."
    },
    "Shares Outstanding (Basic)": {
      "concepts": [
        "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
        "us-gaap:CommonStockSharesOutstanding"
      ],
      "notes": "Basic share count. Weighted average for income statement, point-in-time for balance sheet."
    },
    "Shares Outstanding (Diluted)": {
      "concepts": [
        "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
        "us-gaap:WeightedAverageNumberOfSharesOutstandingDilutedDiscontinuedOperations"
      ],
      "notes": "Diluted share count including options, warrants, convertible debt."
    },
    "Revenue": {
      "concepts": [
        "us-gaap:Revenues",
        "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
        "us-gaap:SalesRevenueNet",
        "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax"
      ],
      "notes": "Total revenue. Many pre-commercial biotechs have $0 revenue."
    },
    "Net Income (Loss)": {
      "concepts": [
        "us-gaap:NetIncomeLoss",
        "us-gaap:ProfitLoss"
      ],
      "notes": "Bottom line. Usually negative for pre-commercial biotechs."
    },
    "Total Assets": {
      "concepts": [
        "us-gaap:Assets"
      ],
      "notes": "Total assets from balance sheet."
    },
    "Total Liabilities": {
      "concepts": [
        "us-gaap:Liabilities"
      ],
      "notes": "Total liabilities from balance sheet."
    },
    "Stockholders Equity": {
      "concepts": [
        "us-gaap:StockholdersEquity",
        "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
      ],
      "notes": "Shareholder equity. Important for runway calculations."
    },
    "Cost of Revenue": {
      "concepts": [
        "us-gaap:CostOfRevenue",
        "us-gaap:CostOfGoodsAndServicesSold",
        "us-gaap:CostOfGoodsSold"
      ],
      "notes": "COGS. Many pre-commercial biotechs have $0."
    },
    "Gross Profit": {
      "concepts": [
        "us-gaap:GrossProfit"
      ],
      "notes": "Revenue - COGS. May not be reported if pre-commercial."
    },
    "Operating Income (Loss)": {
      "concepts": [
        "us-gaap:OperatingIncomeLoss",
        "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
      ],
      "notes": "Income from operations before taxes."
    },
    "Interest Expense": {
      "concepts": [
        "us-gaap:InterestExpense",
        "us-gaap:InterestExpenseDebt"
      ],
      "notes": "Interest paid on debt."
    },
    "Income Tax Expense": {
      "concepts": [
        "us-gaap:IncomeTaxExpenseBenefit"
      ],
      "notes": "Tax expense/benefit."
    },
    "Cash Flow from Operations": {
      "concepts": [
        "us-gaap:NetCashProvidedByUsedInOperatingActivities"
      ],
      "notes": "Operating cash flow - critical for burn analysis."
    },
    "Cash Flow from Investing": {
      "concepts": [
        "us-gaap:NetCashProvidedByUsedInInvestingActivities"
      ],
      "notes": "Investing activities cash flow."
    },
    "Cash Flow from Financing": {
      "concepts": [
        "us-gaap:NetCashProvidedByUsedInFinancingActivities"
      ],
      "notes": "Financing activities cash flow (fundraising)."
    },
    "Capital Expenditures": {
      "concepts": [
        "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment"
      ],
      "notes": "Capex - facility/equipment purchases."
    },
    "Depreciation and Amortization": {
      "concepts": [
        "us-gaap:DepreciationDepletionAndAmortization",
        "us-gaap:Depreciation",
        "us-gaap:DepreciationAndAmortization"
      ],
      "notes": "D&A expense."
    },
    "Stock-Based Compensation": {
      "concepts": [
        "us-gaap:AllocatedShareBasedCompensationExpense",
        "us-gaap:ShareBasedCompensation"
      ],
      "notes": "Stock-based comp expense."
    },
    "Accounts Receivable": {
      "concepts": [
        "us-gaap:AccountsReceivableNetCurrent"
      ],
      "notes": "A/R for commercial-stage companies."
    },
    "Inventory": {
      "concepts": [
        "us-gaap:InventoryNet"
      ],
      "notes": "Inventory for commercial-stage companies."
    },
    "Prepaid Expenses": {
      "concepts": [
        "us-gaap:PrepaidExpenseAndOtherAssetsCurrent"
      ],
      "notes": "Prepaid expenses and other current assets."
    },
    "Property Plant and Equipment": {
      "concepts": [
        "us-gaap:PropertyPlantAndEquipmentNet"
      ],
      "notes": "PP&E net of depreciation."
    },
    "Intangible Assets": {
      "concepts": [
        "us-gaap:IntangibleAssetsNetExcludingGoodwill",
        "us-gaap:FiniteLivedIntangibleAssetsNet"
      ],
      "notes": "Intangible assets (patents, licenses)."
    },
    "Goodwill": {
      "concepts": [
        "us-gaap:Goodwill"
      ],
      "notes": "Goodwill from acquisitions."
    },
    "Accounts Payable": {
      "concepts": [
        "us-gaap:AccountsPayableCurrent"
      ],
      "notes": "Current A/P."
    },
    "Accrued Liabilities": {
      "concepts": [
        "us-gaap:AccruedLiabilitiesCurrent",
        "us-gaap:OtherLiabilitiesCurrent"
      ],
      "notes": "Accrued expenses and other current liabilities."
    },
    "Deferred Revenue": {
      "concepts": [
        "us-gaap:DeferredRevenue",
        "us-gaap:ContractWithCustomerLiabilityCurrent"
      ],
      "notes": "Deferred/unearned revenue."
    },
    "Accumulated Deficit": {
      "concepts": [
        "us-gaap:RetainedEarningsAccumulatedDeficit"
      ],
      "notes": "Accumulated deficit (negative retained earnings)."
    },
    "Common Stock Shares Outstanding": {
      "concepts": [
        "us-gaap:CommonStockSharesOutstanding"
      ],
      "notes": "Common shares outstanding (point in time)."
    },
    "EPS Basic": {
      "concepts": [
        "us-gaap:EarningsPerShareBasic"
      ],
      "notes": "Basic earnings per share."
    },
    "EPS Diluted": {
      "concepts": [
        "us-gaap:EarningsPerShareDiluted"
      ],
      "notes": "Diluted earnings per share."
    }
  }
}
